Drug Profile
Research programme: Parkinson's disease therapeutics - TauRx Therapeutics
Alternative Names: G2 PD; TRx 018Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator TauRx Therapeutics
- Class
- Mechanism of Action Synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Parkinson's-disease in Singapore
- 01 Feb 2016 Early research development is ongoing in Singapore (TauRx Therapeutics pipeline, February 2016)
- 30 Jun 2011 Preclinical trials in Parkinson's disease in Singapore (unspecified route)